Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 7/20 | 0.47 |
| ▸ | LIPG | Q9Y5X9 | 7/20 | 0.47 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.38 |
| ▸ | PNLIP | P16233 | 2/20 | 0.37 |
| ▸ | P4HB | P07237 | 1/20 | 0.36 |
| ▸ | CSF1R | P07333 | 1/20 | 0.36 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.36 |
| ▸ | TTR | P02766 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1129289 | 0.87 | LIPG (0.49) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL1129141 | 0.83 | TTR (0.48) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL4366318 | 0.83 | LPL (0.47) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL1129150 | 0.83 | TTR (0.48) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL17423585 | 0.82 | LPL (0.50) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL6865570 | 0.80 | LMNA (0.49) | LPLLIPGCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL6861464 | 0.80 | LPL (0.44) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL28738862 | 0.80 | DGAT1 (0.51) | LPLLIPGAAK1DGAT1MRGPRX4 | |
| SCHEMBL1129409 | 0.79 | LIPG (0.43) | LPLLIPGAAK1CA1CA2 | |
| SCHEMBL5899727 | 0.78 | LPL (0.65) | LPLLIPGCA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9694011-B2 | Substituted pyrazolopyrimidines as kinases inhibitors | JIANGSU MEDOLUTION LTD (CN) | 2017-07-04 | — | — | US | disclosed |
| US-9694011-B2 | Substituted pyrazolopyrimidines as kinases inhibitors | JIANGSU MEDOLUTION LTD (CN) | 2017-07-04 | — | — | US | disclosed |
| US-9694011-B2 | Substituted pyrazolopyrimidines as kinases inhibitors | JIANGSU MEDOLUTION LTD (CN) | 2017-07-04 | — | — | US | disclosed |
| US-20160120868-A1 | SUBSTITUTED PYRAZOLOPYRIMIDINES AS KINASES INHIBITORS | JIANGSU MEDOLUTION LTD. (CN) | 2016-05-05 | — | — | US | disclosed |
| US-20160120868-A1 | SUBSTITUTED PYRAZOLOPYRIMIDINES AS KINASES INHIBITORS | JIANGSU MEDOLUTION LTD. (CN) | 2016-05-05 | — | — | US | disclosed |
| US-20160120868-A1 | SUBSTITUTED PYRAZOLOPYRIMIDINES AS KINASES INHIBITORS | JIANGSU MEDOLUTION LTD. (CN) | 2016-05-05 | — | — | US | disclosed |
| EP-2999702-A1 | SUBSTITUTED PYRAZOLOPYRIMIDINES AS KINASES INHIBITORS | Jiangsu Medolution Ltd. (CN) | 2016-03-30 | — | — | EP | disclosed |
| US-8481733-B2 | Substituted imidazopyr- and imidazotri-azines | OSI Pharmaceuticals, LLC (US) | 2013-07-09 | — | — | US | disclosed |
| EP-2283020-B1 | SUBSTITUTED IMIDAZOPYR-AND IMIDAZOTRI-AZINES | OSI PHARM INC (US) | 2012-10-31 | — | — | EP | disclosed |
| US-20090286768-A1 | SUBSTITUTED IMIDAZOPYR- AND IMIDAZOTRI-AZINES | OSI PHARMACEUTICALS, INC. (US) | 2009-11-19 | — | — | US | disclosed |
| US-6713474-B2 | SERINE-THREONINE AND TYROSINE KINASE INHIBITORS | ABBOTT GMBH & CO. KG (DE) | 2004-03-30 | — | — | US | disclosed |
| US-20030153752-A1 | Pyrrolopyrimidines as therapeutic agents | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2003-08-14 | — | — | US | disclosed |
| WO-2001072751-A1 | PYRROLOPYRIMIDINES AS TYROSINE KINASE INHIBITORS | KNOLL GESELLSCHAFT MIT BESCHRAENKTER HAFTUNG (DE) | 2001-10-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160120868-A1 | SUBSTITUTED PYRAZOLOPYRIMIDINES AS KINASES INHIBITORS | BTK, LCK, ABL1 | LPL 3126/4885LIPG 2681/4885AAK1 323/4885 |
| US-20030153752-A1 | Pyrrolopyrimidines as therapeutic agents | FLT1, FLT4, TFPI | LPL 3780/4885LIPG 2107/4885AAK1 871/4885 |
| US-20090286768-A1 | SUBSTITUTED IMIDAZOPYR- AND IMIDAZOTRI-AZINES | ABL1, TPMT, CYP2C19 | LPL 4530/4885LIPG 4744/4885AAK1 1736/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.